How U.S. insurance companies are blocking COVID-19 mutation surveillance


The United States is not at the top of its game when it comes to coronavirus sequencing, which makes tracking COVID-19 mutations a challenge, Bloomberg reports. That's a real concern as the Delta variant and other potentially concerning variants spread around the U.S. and the world.
Part of the reason the U.S. lags behind other countries when it comes to mutation surveillance is because sequencing positive tests isn't mandatory, Jade Fulce, a spokeswoman for the Centers for Disease Control and Prevention, told Bloomberg. Therefore, the agency doesn't receive sufficient data from specific states or jurisdictions, forcing scientists to rely on "geographically broad regions," instead.
Per Bloomberg, health insurers may need to enter the fray to "achieve truly widespread adoption" of sequencing. Right now, they don't pay for it because even in the case that a mutated form of the coronavirus is discovered in a patient (federal regulations prevent labs from telling doctors what variant their patients have unless they're participating in a study, so this is rare), mutations don't alter treatment plans. "It's not approved as a medical health activity," James Crawford, senior vice president of laboratory services at the New York-based health-care provider Northwell Health, told Bloomberg. "We have not bridged that gap."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
If sequencing does increase, though, and researchers begin to identify interventions specific to mutated forms of the virus, insurance companies would have reason to cover the process, Bloomberg reports. Read more at Bloomberg.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
An ingredient in Coca-Cola may be funding Sudan's war
Under the Radar Global trade in gum arabic centres on the African nation – and proceeds bankroll conflict between the army and paramilitary rebels
By Harriet Marsden, The Week UK Published
-
Homes for multi-generational families
Feature Featuring a 1900 Jacobean-style mansion in Massachusetts and a 22.5-acre compound in California
By The Week US Published
-
The Week contest: Foot PSA
Puzzles and Quizzes
By The Week US Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published